Biopharmaceutical company Affibody and GE Healthcare are collaborating to develop and bring to market Affibody's PET imaging tracers.
The company's ABY-025 is a HER2-detecting PET imaging tracer under clinical development, Affibody said. It is for use in diagnosing metastatic breast cancer, according to the firm.
Affibody is also developing PD-L1, a binding molecule that would be used to improve selection and monitoring of patients with immuno-oncology treatments, and will work with GE on clinical proof-of-concept studies.
